{"id":"brca","name":"BRCA1 / BRCA2 (HRD)","symbol":"BRCA1, BRCA2","route":"/targets/brca/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000012048","uniprot":"https://www.uniprot.org/uniprotkb/P38398/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P38398","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL5990","open-targets":"https://platform.opentargets.org/target/ENSG00000012048","civic":"https://civicdb.org/genes/672/summary","oncokb":"https://www.oncokb.org/gene/BRCA1","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BRCA1","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=BRCA1","depmap":"https://depmap.org/portal/gene/BRCA1?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000012048-BRCA1","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/672","omim":"https://www.omim.org/entry/113705"},{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000139618","uniprot":"https://www.uniprot.org/uniprotkb/P51587/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P51587","open-targets":"https://platform.opentargets.org/target/ENSG00000139618","civic":"https://civicdb.org/genes/675/summary","oncokb":"https://www.oncokb.org/gene/BRCA2","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BRCA2","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=BRCA2","depmap":"https://depmap.org/portal/gene/BRCA2?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000139618-BRCA2","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/675","omim":"https://www.omim.org/entry/600185"}],"products":[{"id":"bracanalysis-cdx","name":"BRACAnalysis CDx","status":"approved","modality":"Germline BRCA1/2 sequencing companion diagnostic test","route":"/drugs/bracanalysis-cdx/"},{"id":"mychoice-cdx","name":"myChoice CDx","status":"approved","modality":"Tumour HRD genomic instability companion diagnostic test","route":"/drugs/mychoice-cdx/"},{"id":"olaparib","name":"Olaparib","status":"approved","modality":"Small-molecule PARP inhibitor","route":"/drugs/olaparib/"},{"id":"rucaparib","name":"Rucaparib","status":"approved","modality":"Small-molecule PARP inhibitor","route":"/drugs/rucaparib/"},{"id":"talazoparib","name":"Talazoparib","status":"approved","modality":"Small-molecule PARP inhibitor","route":"/drugs/talazoparib/"},{"id":"veliparib","name":"Veliparib","status":"negative","modality":"Small-molecule PARP inhibitor (weak PARP trapper)","route":"/drugs/veliparib/"}],"trials":[{"id":"nct05171816","name":"Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)","nct":"NCT05171816","phase":"3","status":"active"},{"id":"duo-e","name":"DUO-E / GOG-3041 / ENGOT-EN10","nct":"NCT04269200","phase":"3","status":"positive"},{"id":"duo-o","name":"DUO-O / ENGOT-ov46","nct":"NCT03737643","phase":"3","status":"mixed"},{"id":"talapro-2","name":"TALAPRO-2","nct":"NCT03395197","phase":"3","status":"positive"},{"id":"triton3","name":"TRITON3","nct":"NCT02975934","phase":"3","status":"mixed"},{"id":"athena-mono","name":"ATHENA-MONO / GOG-3020","nct":"NCT03522246","phase":"3","status":"positive"},{"id":"magnitude","name":"MAGNITUDE","nct":"NCT03748641","phase":"3","status":"mixed"},{"id":"propel","name":"PROpel","nct":"NCT03732820","phase":"3","status":"positive"},{"id":"olympia","name":"OlympiA","nct":"NCT02032823","phase":"3","status":"positive"},{"id":"brocade3","name":"BROCADE3","nct":"NCT02163694","phase":"3","status":"mixed"},{"id":"profound","name":"PROfound","nct":"NCT02987543","phase":"3","status":"positive"},{"id":"paola-1","name":"PAOLA-1 / ENGOT-ov25","nct":"NCT02477644","phase":"3","status":"positive"},{"id":"polo","name":"POLO","nct":"NCT02184195","phase":"3","status":"mixed"},{"id":"brightness","name":"BrighTNess","nct":"NCT02032277","phase":"3","status":"completed"},{"id":"embraca","name":"EMBRACA","nct":"NCT01945775","phase":"3","status":"positive"},{"id":"nct01874353","name":"Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy","nct":"NCT01874353","phase":"3","status":"active"},{"id":"solo-1","name":"SOLO-1","nct":"NCT01844986","phase":"3","status":"positive"},{"id":"tnt","name":"TNT (Triple Negative Trial)","nct":"NCT00532727","phase":"3","status":"mixed"},{"id":"olympiad","name":"OlympiAD","nct":"NCT02000622","phase":"3","status":"positive"},{"id":"nct05059522","name":"Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing","nct":"NCT05059522","phase":"3","status":"active"},{"id":"nct04884360","name":"D9319C00001- 1L OC Mono Global RCT","nct":"NCT04884360","phase":"3","status":"active"},{"id":"nct03784014","name":"Molecular Profiling of Advanced Soft-tissue Sarcomas","nct":"NCT03784014","phase":"3","status":"completed"},{"id":"nct07486687","name":"Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy","nct":"NCT07486687","phase":"3","status":"planned"},{"id":"nct06915025","name":"Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Pat","nct":"NCT06915025","phase":"3","status":"recruiting"},{"id":"nct04624204","name":"Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-","nct":"NCT04624204","phase":"3","status":"active"},{"id":"nct04421963","name":"Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib","nct":"NCT04421963","phase":"3","status":"active"},{"id":"nct04380636","name":"Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)","nct":"NCT04380636","phase":"3","status":"active"},{"id":"nct04821622","name":"Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC","nct":"NCT04821622","phase":"3","status":"active"},{"id":"partner","name":"PARTNER","nct":"NCT03150576","phase":"2/3","status":"positive"},{"id":"rainbo","name":"RAINBO","nct":"NCT05255653","phase":"2/3","status":"recruiting"},{"id":"pediatric-match","name":"NCI-COG Pediatric MATCH (APEC1621)","nct":"NCT03155620","phase":"platform","status":"active"},{"id":"lung-map","name":"Lung-MAP (SWOG S1400 and S1900)","nct":"NCT02154490","phase":"platform","status":"completed"},{"id":"i-spy-2","name":"I-SPY 2","nct":"NCT01042379","phase":"platform","status":"active"},{"id":"precision-panc","name":"Precision-Panc","nct":"ISRCTN14879538","phase":"platform","status":"completed"},{"id":"nct03742895","name":"Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)","nct":"NCT03742895","phase":"2","status":"active"},{"id":"nct04042831","name":"Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations","nct":"NCT04042831","phase":"2","status":"active"},{"id":"nct03334617","name":"Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy","nct":"NCT03334617","phase":"2","status":"active"},{"id":"cupisco","name":"CUPISCO","nct":"NCT03498521","phase":"2","status":"positive"},{"id":"nct03459846","name":"A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)","nct":"NCT03459846","phase":"2","status":"active"},{"id":"nct03330847","name":"To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.","nct":"NCT03330847","phase":"2","status":"active"},{"id":"plasmamatch","name":"plasmaMATCH","nct":"NCT03182634","phase":"2","status":"completed"},{"id":"tapur","name":"TAPUR (Targeted Agent and Profiling Utilization Registry)","nct":"NCT02693535","phase":"2","status":"recruiting"},{"id":"nct01081951","name":"Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitax","nct":"NCT01081951","phase":"2","status":"active"},{"id":"nct04683679","name":"A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negat","nct":"NCT04683679","phase":"2","status":"recruiting"},{"id":"nct07024784","name":"A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN1","nct":"NCT07024784","phase":"2","status":"recruiting"},{"id":"nct04858334","name":"APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a","nct":"NCT04858334","phase":"2","status":"recruiting"},{"id":"nct07005583","name":"Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent","nct":"NCT07005583","phase":"2","status":"planned"},{"id":"nct06686030","name":"Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer","nct":"NCT06686030","phase":"2","status":"recruiting"},{"id":"nct06909825","name":"FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","nct":"NCT06909825","phase":"2","status":"active"},{"id":"nct06419179","name":"Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extens","nct":"NCT06419179","phase":"2","status":"recruiting"},{"id":"nct05485766","name":"Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer","nct":"NCT05485766","phase":"2","status":"recruiting"},{"id":"nct05522491","name":"Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer","nct":"NCT05522491","phase":"2","status":"planned"},{"id":"nct05222971","name":"Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy","nct":"NCT05222971","phase":"2","status":"recruiting"},{"id":"nct05623319","name":"Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)","nct":"NCT05623319","phase":"2","status":"recruiting"},{"id":"nct05093231","name":"Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer","nct":"NCT05093231","phase":"2","status":"recruiting"},{"id":"nct06245889","name":"PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC","nct":"NCT06245889","phase":"2","status":"recruiting"},{"id":"phoenix","name":"PHOENIX DDR/Anti-PD-L1","nct":"NCT03740893","phase":"2","status":"recruiting"},{"id":"nct03775486","name":"Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)","nct":"NCT03775486","phase":"2","status":"active"},{"id":"nct05498155","name":"Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer","nct":"NCT05498155","phase":"2","status":"active"},{"id":"nct05725200","name":"Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer","nct":"NCT05725200","phase":"2","status":"recruiting"},{"id":"nct05128734","name":"Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)","nct":"NCT05128734","phase":"2","status":"planned"},{"id":"nct04644289","name":"WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC","nct":"NCT04644289","phase":"2","status":"recruiting"},{"id":"nct02734004","name":"A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.","nct":"NCT02734004","phase":"1/2","status":"active"},{"id":"nct06525298","name":"EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors","nct":"NCT06525298","phase":"1/2","status":"recruiting"},{"id":"nct07453394","name":"QLS5132 Combination Therapy in Advanced Solid Tumors","nct":"NCT07453394","phase":"1/2","status":"planned"},{"id":"nct05035745","name":"Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)","nct":"NCT05035745","phase":"1/2","status":"recruiting"},{"id":"nct05898399","name":"Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)","nct":"NCT05898399","phase":"1/2","status":"recruiting"},{"id":"nct05933265","name":"Study of LP-184 in Patients With Advanced Solid Tumors","nct":"NCT05933265","phase":"1/2","status":"active"},{"id":"nct02861573","name":"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)","nct":"NCT02861573","phase":"1/2","status":"active"},{"id":"nct06353386","name":"Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)","nct":"NCT06353386","phase":"1/2","status":"recruiting"},{"id":"europac","name":"EUROPAC","nct":"ISRCTN62546421","phase":"observational","status":"recruiting"}],"pathways":["base-excision-repair-parp","breast-cancer-signalling","ddr","homologous-recombination-repair","mutagenesis-signatures","pancreatic-cancer-signalling","synthetic-lethality-map"],"companies":["abbvie","astrazeneca","merck","myriad-genetics","pfizer","pharmaand"],"keyPapers":["paper-conroy-nhs-r208-mainstream-testing-audit-breast-j-2026","paper-olympia-6-year-update-ann-oncol-2026","paper-hudson-phillips-expanded-germline-testing-clin-breast-cancer-2026","paper-erices-chilean-gallbladder-landscape-front-oncol-2025","paper-bedrosian-asco-sso-germline-testing-breast-jco-2024","paper-fizazi-triton3-rucaparib-nejm-2023","paper-asco-biomarkers-metastatic-breast-cancer-guideline-jco-2022","paper-giraldo-gallbladder-msk-impact-ccr-2022","paper-olympia-overall-survival-ann-oncol-2022","paper-polo-overall-survival-olaparib-gbrca-pancreatic-jco-2022","paper-jensen-clonal-haematopoiesis-cfdna-interference-prostate-jama-oncol-2021","paper-bardia-ascent-trop2-biomarker-ann-oncol-2021","paper-tukachinsky-ctdna-3334-advanced-prostate-ccr-2021","paper-olympia-nejm-2021","paper-reiss-rucaparib-maintenance-brca-palb2-pancreatic-jco-2021","paper-park-hrd-pancreatic-platinum-ccr-2020","paper-mateo-genomics-lethal-prostate-diagnosis-castration-resistance-jci-2020","paper-asco-hereditary-breast-cancer-guideline-jco-2020","paper-caps-consortium-surveillance-recommendations-gut-2020","paper-pishvaian-lancet-oncol","paper-profound-nejm-2020","paper-abida-triton2-rucaparib-brca-jco-2020","paper-bertucci-metastatic-breast-genomics-nature-2019","paper-yurgelun-germline-second-hits-resected-pancreatic-genet-med-2019","paper-weinberg-biliary-profiling-jgo-2019","paper-paola-1-nejm-2019","paper-polo-olaparib-maintenance-gbrca-pancreatic-nejm-2019","paper-nicolosi-germline-variants-prostate-testing-guidelines-jama-oncol-2019","paper-chung-comprehensive-genomic-profiling-prostate-jco-po-2019","paper-singhi-targeted-genome-profiling-3594-pdac-gastroenterology-2019","paper-staaf-tnbc-whole-genome-scan-b-nat-med-2019","paper-hu-germline-mutations-pancreatic-cancer-risk-jama-2018","paper-tutt-nat-med","paper-annala-ctdna-resistance-abiraterone-enzalutamide-cancer-discov-2018","paper-wardell-biliary-drivers-germline-j-hepatol-2018","paper-quigley-structural-variation-mcrpc-cell-2018","paper-zheng-nigerian-inherited-breast-cancer-jco-2018","paper-isaacsson-velho-intraductal-germline-dna-repair-prostate-2018","paper-lowery-prospective-germline-exocrine-pancreatic-jnci-2018","paper-aguirre-real-time-genomic-characterisation-pancreatic-cancer-discov-2018","paper-solo-1-nejm-2018","paper-shimelis-tnbc-risk-genes-jnci-2018","paper-quigley-brca2-reversion-cfdna-parp-resistance-cancer-discov-2017","paper-connor-mutational-signatures-immune-pancreatic-jama-oncol-2017","paper-wyatt-ctdna-tissue-concordance-mcrpc-jnci-2017","paper-shindo-germline-sporadic-pancreatic-jco-2017","paper-taylor-germline-brca2-evolutionary-trajectories-nat-commun-2017","paper-hahnen-geparsixto-germline-brca-jama-oncol-2017","paper-davies-nat-med","paper-telli-hrd-score-platinum-tnbc-ccr-2016","paper-pritchard-inherited-dna-repair-metastatic-prostate-nejm-2016","paper-roberts-familial-pancreatic-whole-genome-cancer-discov-2016","paper-couch-tnbc-germline-17-genes-jco-2015","paper-robinson-integrative-clinical-genomics-advanced-prostate-cell-2015","paper-tcga-molecular-taxonomy-primary-prostate-cell-2015","paper-villarreal-garza-mexican-tnbc-brca-bcrt-2015","paper-mateo-toparp-a-olaparib-dna-repair-nejm-2015","paper-waddell-whole-genomes-pancreatic-nature-2015","paper-sharma-tnbc-registry-germline-brca-bcrt-2014","paper-golan-brca-pancreatic-platinum-survival-bjc-2014","paper-gabai-kapara-population-brca-screening-pnas-2014","paper-castro-germline-brca-prostate-outcomes-jco-2013","paper-donenberg-bahamas-brca1-founder-bcrt-2011","paper-brca-risk-reducing-surgery-jama-2010","paper-atchley-brca-status-triple-negative-jco-2008","paper-foulkes-brca1-basal-phenotype-jnci-2003","paper-sorlie-repeated-observation-subtypes-brca1-basal-pnas-2003","paper-gorski-brca1-founder-mutations-poland-ajhg-2000","paper-struewing-brca-founder-mutations-ashkenazi-nejm-1997"],"hotspots":[],"openQuestions":[{"id":"brca-parpi-reversion","question":"Should BRCA reversion mutations detected in ctDNA change treatment before radiographic progression on a PARP inhibitor?","stage":"translational","actor":"clinic","source":{"label":"SOLO-1 seven-year overall survival, J Clin Oncol 2023","url":"https://doi.org/10.1200/JCO.22.01549"}}],"assays":[{"id":"foundationone-cdx-panel","name":"FoundationOne CDx","cutoff":"Per companion claim: EGFR, ALK, BRAF V600, ERBB2 amplification, KRAS wild-type, BRCA1/2 and HRR genes, PIK3CA, MET exon 14, RET, FGFR2 fusions, IDH1, NTRK fusions; MSI-high; TMB at least 10 mutations per megabase"},{"id":"foundationone-liquid-cdx","name":"FoundationOne Liquid CDx","cutoff":"Per companion claim: EGFR (osimertinib, erlotinib, gefitinib), ALK (alectinib), BRCA1/2 and ATM (olaparib, rucaparib), PIK3CA (alpelisib), FGFR3 (erdafitinib), NTRK and RET; negative plasma results reflex to tissue"},{"id":"bracanalysis-cdx","name":"BRACAnalysis CDx","cutoff":"Deleterious or suspected deleterious germline variant"},{"id":"mychoice-cdx","name":"myChoice CDx","cutoff":"Genomic instability score at least 42, or BRCA1/2 mutation, defines HRD-positive (olaparib plus bevacizumab, PAOLA-1; niraparib)"},{"id":"foundationfocus-brca","name":"FoundationFocus CDxBRCA","cutoff":"Deleterious BRCA1/2 alteration (rucaparib, ovarian cancer)"}],"resistance":[{"class":"parp-inhibitor","mechanism":"BRCA1/2 reversion mutations","category":"bypass"},{"class":"parp-inhibitor","mechanism":"Restoration of HR via 53BP1/Shieldin loss","category":"bypass"},{"class":"parp-inhibitor","mechanism":"Replication fork protection and PARP1 loss","category":"on-target"},{"class":"parp-inhibitor","mechanism":"Drug efflux (ABCB1)","category":"pharmacology"},{"class":"ar-pathway","mechanism":"AR amplification and ligand-binding-domain mutations","category":"on-target"},{"class":"ar-pathway","mechanism":"AR splice variants (AR-V7)","category":"on-target"},{"class":"ar-pathway","mechanism":"Lineage plasticity to neuroendocrine prostate cancer","category":"lineage"},{"class":"ar-pathway","mechanism":"PI3K/AKT activation via PTEN loss","category":"bypass"},{"class":"ar-pathway","mechanism":"Glucocorticoid receptor substitution","category":"bypass"}],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}